Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 06, 2025 08:00 ET | Source: Recursion Pharmaceuticals

Recursion to Participate in Upcoming Investor Conferences

Salt Lake City, May 06, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today its participation in...
May 05, 2025 06:00 ET | Source: Recursion Pharmaceuticals

Recursion Reports First Quarter 2025 Financial Results and Provides Business Update

Pipeline: Delivered on our commitment to a more focused R&D strategy by advancing a streamlined portfolio of 5+ clinical and preclinical programs in oncology and rare disease, while deprioritizing...
April 28, 2025 08:27 ET | Source: Recursion Pharmaceuticals

Recursion to Report First Quarter 2025 Business Updates and Financial Results on May 5th

Salt Lake City, UT, April 28, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today it will provide...
April 22, 2025 20:34 ET | Source: Recursion Pharmaceuticals

Recursion to Present Preliminary Clinical Data from the Ongoing Phase 1b/2 trial of REC-4881 in FAP at Digestive Disease Week 2025

Salt Lake City, UT, April 22, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, will present preliminary data...
April 09, 2025 08:00 ET | Source: Recursion Pharmaceuticals

Recursion and Enamine Release New AI-Enabled Targeted Compound Libraries

Kyiv, Ukraine and Salt Lake City, UT, April 09, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, today...
April 08, 2025 08:00 ET | Source: Recursion Pharmaceuticals

Recursion Announces First Patient Dosed in Phase 1 Clinical Study of REC-3565, a Selective MALT1 Inhibitor for Relapsed or Refractory B-cell Lymphomas

Salt Lake City, UT, April 08, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, today announced that the first...
April 01, 2025 08:00 ET | Source: Recursion Pharmaceuticals

Recursion to Participate in Upcoming Investor Conference

Salt Lake City, UT, April 01, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, announced today its...
March 18, 2025 08:00 ET | Source: Recursion Pharmaceuticals

Recursion Bolsters Board of Directors with Former FDA Principal Deputy Commissioner Dr. Namandjé Bumpus and Mammoth Biosciences COO and CFO Elaine Sun

Salt Lake City, UT, March 18, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, today announced that Namandjé...
February 28, 2025 06:30 ET | Source: Recursion Pharmaceuticals

Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2024 Financial Results

Reported promising safety and preliminary efficacy data for REC-617, an oral CDK7 inhibitor, and met primary endpoints and demonstrated encouraging trends in efficacy for REC-994 in cerebral cavernous...
February 24, 2025 08:00 ET | Source: Recursion Pharmaceuticals

Recursion to Report Fourth Quarter and Fiscal Year 2024 Business Updates and Financial Results on February 28th

Salt Lake City, UT, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, announced today it will...

Next Page keyboard_arrow_right